• The study compound is a new compound. It may potentially be used for the treatment of health problems related to (severe) overweight. The study compound is a medicine that is similar to a hormone called amylin. This hormone is produced by the body itself and is released after a meal. Amylin makes you feel full, less hungry and helps your body lower the amount of sugar in the blood.
• This is the first study in which the study compound is being administered in humans; in other parts of this study the study compound is already been administered to 70 humans.
• You will receive the study compound for 26 weeks. You will receive the study compound in the research center, but also take it at home. During the study, you will be required to keep a diary of the medication you take at home.

All (potential) medicines can cause side effects. Since this is the first study in which the investigational drug is being tested in humans, no side effects have yet been observed in humans. It is also unknown whether and how often these side effects may occur. In rare cases (<0.1%), serious side effects can occur during the first administration to humans. The compound has already been extensively tested in the laboratory and on animals. Prior to the medical screening, you will receive written information about the trial, which also describes the possible side effects based on these animal tests. This information will also be discussed with you at the start of the medical screening. You can then ask the screening physician or nurse any question you may have. The medical screening will only take place after you have given written consent to participate in the trial. We want to emphasize that even after giving written consent, participation in any clinical trial is voluntary. You can decide at any time not to participate or to stop the medical screening or the trial. You do not need to provide a reason for why you no longer wish to participate.

At the start of the screening visit, you are only allowed to have consumed water for 4 hours. This means that, before any potential participation in the study, we will already ask you not to eat for a certain period of time. You have not yet signed the form for participation in the trial. After the screening it will be announced whether you can participate.

You will receive a gross compensation of € 20.158 for full participation in the study.

Travel expenses will be reimbursed based on the distance traveled (€ 0.23 per kilometer) with a minimum of € 14.23 and a maximum of € 193.20 (840 kilometers) per round trip, regardless of the mode of transportation.